FDA's Reversal on Gene Therapy Helps My Son
I'm concerned about the recent debate surrounding Elevidys and gene therapies like it. The death of any patient participating in a clinical trial is heartbreaking. Such tragedies and regulatory reactions to them risk casting a shadow over therapies like Elevidys.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Exact Sciences (EXAS) To Report Earnings Tomorrow: Here Is What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close. Here's what to expect. Exact Sciences beat analysts' revenue expectations by 2.7% last quarter, reporting revenues of $706.8 million, up 10.9% year on year. It was a satisfactory quarter for the company, with full-year revenue guidance slightly topping analysts' expectations but a significant miss of analysts' EPS estimates. Is Exact Sciences a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Exact Sciences's revenue to grow 10.6% year on year to $773.1 million, slowing from the 12.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Exact Sciences has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average. Looking at Exact Sciences's peers in the biotechnology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Regeneron delivered year-on-year revenue growth of 3.6%, beating analysts' expectations by 11.3%, and Incyte reported revenues up 16.5%, topping estimates by 5.5%. Regeneron traded up 4.8% following the results while Incyte was also up 10.5%. Read our full analysis of Regeneron's results here and Incyte's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Exact Sciences is down 9.1% during the same time and is heading into earnings with an average analyst price target of $68.55 (compared to the current share price of $47.70). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Oscar Health (OSCR) Q2 Earnings: What To Expect
Health insurance company Oscar Health (NYSE:OSCR) will be reporting earnings this Wednesday morning. Here's what to expect. Oscar Health beat analysts' revenue expectations by 6.9% last quarter, reporting revenues of $3.05 billion, up 42.1% year on year. It was a stunning quarter for the company, with a solid beat of analysts' EPS estimates. Is Oscar Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Oscar Health's revenue to grow 33.7% year on year to $2.97 billion, slowing from the 46% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.84 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Oscar Health has missed Wall Street's revenue estimates four times over the last two years. Looking at Oscar Health's peers in the health insurance providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.4%, beating analysts' expectations by 5.1%, and Alignment Healthcare reported revenues up 49%, topping estimates by 5.7%. CVS Health's stock price was unchanged after the resultswhile Alignment Healthcare was up 5.7%. Read our full analysis of CVS Health's results here and Alignment Healthcare's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Oscar Health is down 17% during the same time and is heading into earnings with an average analyst price target of $11.29 (compared to the current share price of $13.95). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Tennessee readies for execution of man with working implanted defibrillator
NASHVILLE, Tenn. (AP) — Tennessee is gearing up for an execution on Tuesday that experts say would likely mark the first time a man has been put to death with a working defibrillator in his chest. Gov. Bill Lee declined Monday to grant a reprieve, clearing the way for Byron Black's execution after a legal battle and ongoing uncertainty about whether the implantable cardioverter-defibrillator will shock his heart when the lethal drug takes effect. The nonprofit Death Penalty Information Center said it's unaware of any other cases in which a person on death row made similar claims to Black's about defibrillators or pacemakers. Black's attorneys said they haven't found a comparable case, either. Lee said the courts have "universally determined that it is lawful to carry out the jury's sentence of execution given to Mr. Black for the heinous murders of Angela Clay and her daughters Lakeisha, age 6, and Latoya, age 9." The U.S. Supreme Court on Monday rejected Black's appeals. The execution would be Tennessee's second since May, after a pause for five years, first because of COVID-19 and then because of missteps by state corrections officials. Twenty-seven men have died by court-ordered execution so far this year in the U.S., and nine other people are scheduled to be put to death in seven states during the remainder of 2025. The number of executions this year exceeds the 25 carried out last year and in 2018. It is the highest total since 2015, when 28 people were put to death. Black's condition Black, 69, is in a wheelchair, and he has dementia, brain damage, kidney failure, congestive heart failure and other conditions, his attorneys have said. The implantable cardioverter-defibrillator he has is a small, battery-powered electronic device that is surgically implanted in the chest. It serves as a pacemaker and an emergency defibrillator. Black's attorneys say in order to be sure it's off, a doctor must place a programming device over the implant site, sending it a deactivation command, with no surgery required. In mid-July, a trial court judge agreed with Black's attorneys that officials must have his device deactivated to avert the risk that it could cause unnecessary pain and prolong the execution. But the state Supreme Court intervened July 31 to overturn that decision, saying the other judge lacked the authority to order the change. The state has disputed that the lethal injection would cause Black's defibrillator to shock him. Even if shocks were triggered, Black wouldn't feel them, the state said. Black's attorneys have countered that even if the lethal drug being used, pentobarbital, renders someone unresponsive, they aren't necessarily unaware or unable to feel pain. Kelley Henry, Black's attorney, said the execution could become a 'grotesque spectacle.' The legal case also spurred a reminder that most medical professionals consider participation in executions a violation of health care ethics. Black's case Black was convicted in the 1988 shooting deaths of his girlfriend Angela Clay, 29, and her two daughters. Prosecutors said he was in a jealous rage when he shot the three at their home. At the time, Black was on work-release while serving time for shooting Clay's estranged husband. Linette Bell, whose sister and two nieces were killed, recently told WKRN-TV: 'He didn't have mercy on them, so why should we have mercy on him?' Intellectual disability claim In recent years, Black's legal team has unsuccessfully tried to get a new hearing over whether he is intellectually disabled and ineligible for the death penalty under U.S. Supreme Court precedent. His attorneys have said that if they had delayed a prior attempt to seek his intellectual disability claim, he would have been spared under a 2021 state law. Nashville District Attorney Glenn Funk contended in 2022 that Black is intellectually disabled and deserved a hearing under that 2021 law, but the judge denied it. That is because the 2021 law denies a hearing to people on death row who have already filed a similar request and a court has ruled on it 'on the merits." In Funk's attempt, he focused on input from an expert for the state in 2004 who determined back then that Black didn't meet the criteria for what was then called "mental retardation.' But she concluded that Black met the new law's criteria for a diagnosis of intellectual disability. Black also sought a determination by the courts that he is incompetent to be executed.
